Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224.
Division of Environmental Health Sciences School of Public Health, University of Minnesota MMC 807, Room 1239 Mayo, 420 Delaware Street SE Minneapolis, MN 55455.
Health Phys. 2021 Aug 1;121(2):160-165. doi: 10.1097/HP.0000000000001425.
Lutetium Dotatate radiopharmaceutical therapy (Lutathera) was approved by the United States Food and Drug Administration in 2018 and is used to treat somatostatin receptor positive neuroendocrine tumors. With all new radiopharmaceutical therapies, the radiation exposure to members of the public from the patient who received the therapy must be within regulatory limits and safe. If the patient will expose members of the public to too much radiation, the therapy must be performed on an inpatient basis. This paper shows that the administration of Lutathera can be done on an outpatient basis and provides safety and travel restrictions that should be communicated to the patient prior to leaving. The guidance presented herein serves as a basis for medical institutions looking to use Lutathera to treat patients.
镥替曲塞放射性药物治疗（乐卫玛）于 2018 年获得美国食品药品监督管理局批准，用于治疗生长抑素受体阳性神经内分泌肿瘤。对于所有新的放射性药物治疗，接受治疗的患者对公众成员的辐射暴露必须在监管范围内且安全。如果患者将使公众成员暴露于过多的辐射下，那么该治疗必须在住院的基础上进行。本文表明，乐卫玛可以在门诊进行管理，并提供了在离开前应告知患者的安全和旅行限制。本文提供的指导意见为希望使用乐卫玛治疗患者的医疗机构提供了依据。
